問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital (在職)

Division of General Internal Medicine

Digestive System Department

更新時間：2023-09-19

黃釧峰Huang, Chung-Feng
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

57Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃釧峰

List

96Cases

2020-12-02 - 2022-07-26

Phase II

Phase llb Multi=Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy a and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis Z Virus(B-Clear)nd Safety

  • Condition/Disease

    Patients with chronic hepatitis B virus

  • Test Drug

    GSK3228836

Participate Sites
4Sites

Recruiting4Sites

2017-11-01 - 2021-12-31

Others

A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment(OAV) in Virologically Suppressed Chronic Hepatitis B Subjects with Renal and/or Hepatic Impairment

  • Condition/Disease

    Chronic viral hepatitis B

  • Test Drug

    Vemlidy Film-coated tablet

Participate Sites
10Sites

Terminated9Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

林俊彥
Linkou Chang Gung Medical Foundation

2017-03-17 - 2023-03-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

  • Condition/Disease

    Nonalcoholic Steatohepatitis

  • Test Drug

    Selonsertib

Participate Sites
5Sites

Terminated4Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2017-03-03 - 2023-02-28

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

  • Condition/Disease

    Nonalcoholic Steatohepatitis(NASH)

  • Test Drug

    Selonsertib

Participate Sites
20Sites

Terminated18Sites

黃志富
Kaohsiung Municipal Gangshan Hospital

未分科

沈一嫻
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2018-08-28 - 2021-04-12

Phase II

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects with Chronic Hepatitis B who are not currently on Treatment

  • Condition/Disease

    Viremic Chronic Hepatitis B

  • Test Drug

    GS-9688 Film-coated Tablets, 1.5mg

Participate Sites
5Sites

Terminated3Sites

莊萬龍
Kaohsiung Municipal Gangshan Hospital

未分科

2019-10-04 - 2020-12-28

Phase I

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GS-4224 in Healthy Volunteers and Subjects with the Chronic Hepatitis B (CHB) Virus

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-4224 Film-coated Tablets, 10mg and 100mg

Participate Sites
4Sites

Recruiting4Sites

2019-07-05 - 2022-03-21

Phase I

A Phase 1b, Open-label, Multi-center Study to Evaluate the Safety, Tolerability and Activity of GS-9688 in Special Populations of Subjects with Chronic Hepatitis B

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-9688 Filmed-coated Tablets

Participate Sites
5Sites

Recruiting5Sites

2023-02-15 - 2025-06-30

Phase I

A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)

  • Condition/Disease

    Chronic Hepatitis B

  • Test Drug

    GS-2829GS-6779

Participate Sites
10Sites

Recruiting10Sites

2018-11-01 - 2025-12-31

Phase III

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

  • Condition/Disease

    advanced stage hepatocellular carcinoma

  • Test Drug

    Keytruda® / Lenvima®

Participate Sites
9Sites

Terminated7Sites

黃怡翔
Taipei Veterans General Hospital

Digestive System Department

1 6 7 8 9 10
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB